cycE/CCNE Cancer Research Results

cycE/CCNE, Cyclin E: Click to Expand ⟱
Source:
Type:
Cyclin E regulates multiple downstream molecules, such as the retinoblastoma susceptibility gene (RB1) and the transcription factor E2F.
Cyclin E (Cyclin E1 and Cyclin E2) is the key regulator of the late G1 → S-phase transition.
Cyclin E is a prognostic marker in breast cancer, its altered expression increased with the increasing stage and grade of the tumor.
Cyclin E is a regulatory protein that plays a critical role in the cell cycle, particularly in the transition from the G1 phase to the S phase. Its expression levels can significantly influence cancer progression and patient prognosis.

Cyclin E expression is frequently elevated in various cancers and is generally associated with poor prognosis. Its role in promoting cell cycle progression makes it a potential biomarker for tumor aggressiveness and patient outcomes.


Var, Various Cancer: Click to Expand ⟱
Cyclooxygenase (COX)-2 overexpression has been noted in various cancers. PI3Ks/AKT pathways are over-activated in several types of cancers.
EGFR altered activity has been noted in various pathological conditions. However, its regulation is an important step in the inhibition of cancer. In this regard, EGCG shows a pivotal role in the inhibition of EGFR activity.
Activating protein-1 transcription factor has been associated with pathogenesis including cancer.
Activation of the sonic hedgehog (Shh) pathway is required for the growth of numerous tissues and organs and recent evidence indicates that this pathway is often recruited to stimulate growth of cancer stem cells (CSCs) and to orchestrate the reprogramming of cancer cells via epithelial mesenchymal transition (EMT). Increased expression of Nanog has been associated with the aggressive nature of certain cancers, highlighting its role in promoting cancer stem cell characteristics.
The aberrant hedgehog (Hh)/GLI signaling pathway causes the formation and progression of a variety of tumors.
The process of cell apoptosis is often accompanied by the destruction of mitochondrial transmembrane potential, which is widely regarded as one of the earliest events in the process of cell apoptosis.
Human malignancies frequently exhibit mutations in the TGF-β pathway, and overactivation of this system is linked to tumor growth by promoting angiogenesis and inhibiting the innate and adaptive antitumor immune responses50.
Several studies have demonstrated that high cyclin D1 expression was observed in cancers including breast, lung, prostate, lymph node and colorectal cancers [23–25].
The oncogene c-myc, which is frequently over-expressed in cancer cells, is involved in the transactivation of most of the glycolytic enzymes including lactate dehydrogenase A (LDHA) and the glucose transporter GLUT1 [51,52]. Thus, c-myc activation is a likely candidate to promote the enhanced glucose uptake and lactate release in the proliferating cancer cell.
Vimentin is overexpressed in various epithelial cancers, including prostate cancer, gastrointestinal tumors, tumors of the central nervous system, breast cancer, malignant melanoma, and lung cancer. Vimentin’s overexpression in cancer correlates well with accelerated tumor growth, invasion, and poor prognosis; however, the role of vimentin in cancer progression remains obscure.
Heat shock proteins (HSPs) are normally induced under environmental stress to serve as chaperones for maintenance of correct protein folding but they are often overexpressed in many cancers, including breast cancer.
Since NQO1 is highly expressed in many solid tumors, including via upregulation of Nrf2, the design of compounds activated by NQO1 and NQO1-targeted drug delivery have been active areas of research.
Since increased Nrf2 gene expression is one of the main mechanisms of cancer cells in resisting chemotherapeutic drugs and survival in oxidative conditions; finding compounds with the ability to suppress Nrf2 gene expression with minimum side effects can be considered an important strategy for increasing the sensitivity of cancer cells to chemotherapy.
Overexpression of c-met stimulates proliferation, migration and invasion in various types of cancer including prostate cancer.
Overexpression of TGFα and EGFR by many carcinomas correlates with the development of cancer metastasis, resistance to chemotherapy and poor prognosis.
More than 50% of human cancers have a mutated nonfunctional p53.


Scientific Papers found: Click to Expand⟱
3383- ART/DHA,    Dihydroartemisinin: A Potential Natural Anticancer Drug
- Review, Var, NA
TumCP↓, Apoptosis↑, TumMeta↓, angioG↓, TumAuto↑, ER Stress↑, ROS↑, Ca+2↑, p38↑, HSP70/HSPA5↓, PPARγ↑, GLUT1↓, Glycolysis↓, PI3K↓, Akt↓, Hif1a↓, PKM2↓, lactateProd↓, GlucoseCon↓, EMT↓, Slug↓, Zeb1↓, ZEB2↓, Twist↓, Snail?, CAFs/TAFs↓, TGF-β↓, p‑STAT3↓, M2 MC↓, uPA↓, HH↓, AXL↓, VEGFR2↓, JNK↑, Beclin-1↑, GRP78/BiP↑, eff↑, eff↑, eff↑, eff↑, eff↑, eff↑, IL4↓, DR5↑, Cyt‑c↑, Fas↑, FADD↑, cl‑PARP↑, cycE/CCNE↓, CDK2↓, CDK4↓, Mcl-1↓, Ki-67↓, Bcl-2↓, CDK6↓, VEGF↓, COX2↓, MMP9↓,
3391- ART/DHA,    Antitumor Activity of Artemisinin and Its Derivatives: From a Well-Known Antimalarial Agent to a Potential Anticancer Drug
- Review, Var, NA
TumCP↓, TumMeta↓, angioG↓, TumVol↓, BioAv↓, Half-Life↓, BioAv↑, eff↑, eff↓, ROS↑, selectivity↑, TumCCA↑, survivin↓, BAX↑, Casp3↓, Casp8↑, Casp9↑, CDC25↓, CycB/CCNB1↓, NF-kB↓, cycD1/CCND1↓, cycE/CCNE↓, E2Fs↓, P21↑, p27↑, ADP:ATP↑, MDM2↓, VEGF↓, IL8↓, COX2↓, MMP9↓, ER Stress↓, cMyc↓, GRP78/BiP↑, DNAdam↑, AP-1↓, MMP2↓, PKCδ↓, Raf↓, ERK↓, JNK↓, PCNA↓, CDK2↓, CDK4↓, TOP2↓, uPA↓, MMP7↓, TIMP2↑, Cdc42↑, E-cadherin↑,
3160- Ash,    Withaferin A: A Pleiotropic Anticancer Agent from the Indian Medicinal Plant Withania somnifera (L.) Dunal
- Review, Var, NA
TumCCA↑, H3↑, P21↑, cycA1/CCNA1↓, CycB/CCNB1↓, cycE/CCNE↓, CDC2↓, CHK1↓, Chk2↓, p38↑, MAPK↑, E6↓, E7↓, P53↑, Akt↓, FOXO3↑, ROS↑, γH2AX↑, MMP↓, mitResp↓, eff↑, TumCD↑, Mcl-1↓, ER Stress↑, ATF4↑, ATF3↑, CHOP↑, NOTCH↓, NF-kB↓, Bcl-2↓, STAT3↓, CDK1↓, β-catenin/ZEB1↓, N-cadherin↓, EMT↓, Cyt‑c↑, eff↑, CDK4↓, p‑RB1↓, PARP↑, cl‑Casp3↑, cl‑Casp9↑, NRF2↑, ER-α36↓, LDHA↓, lipid-P↑, AP-1↓, COX2↓, RenoP↑, PDGFR-BB↓, SIRT3↑, MMP2↓, MMP9↓, NADPH↑, NQO1↑, GSR↑, HO-1↑, *SOD2↑, *Prx↑, *Casp3?, eff↑, Snail↓, Slug↓, Vim↓, CSCs↓, HEY1↓, MMPs↓, VEGF↓, uPA↓, *toxicity↓, CDK2↓, CDK4↓, HSP90↓,
2767- Bos,    The potential role of boswellic acids in cancer prevention and treatment
- Review, Var, NA
*Inflam↓, AntiCan↑, *MAPK↑, *Ca+2↝, p‑ERK↓, TumCI↓, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, p‑RB1↓, *NF-kB↓, *TNF-α↓, NF-kB↓, IKKα↓, MCP1↓, IL1α↓, MIP2↓, VEGF↓, Tf↓, COX2↓, MMP9↓, CXCR4↓, VEGF↓, eff↑, PPARα↓, lipid-P?, STAT3↓, TOP1↓, TOP2↑, 5HT↓, p‑PDGFR-BB↓, PDGF↓, AR↓, DR5↑, angioG↓, DR4↑, Casp3↑, Casp8↑, cl‑PARP↑, eff↑, chemoPv↑, Wnt↓, β-catenin/ZEB1↓, ascitic↓, Let-7↑, miR-200b↑, eff↑, MMP1↓, MMP2↓, eff↑, BioAv↓, BioAv↑, Half-Life↓, toxicity↓, Dose↑, BioAv↑, ChemoSen↑,
5861- CAP,    Anticancer Properties of Capsaicin Against Human Cancer
- Review, Var, NA
*antiOx↑, *Inflam↓, *Obesity↓, chemoPv↑, Apoptosis↑, selectivity↑, TRPV1↑, Ca+2↑, mtDam↑, Cyt‑c↑, P53↑, SIRT1↓, TumCCA↑, P21↑, CDK4↓, CDK6↓, cycE/CCNE↓, angioG↓, TumMeta↓,
1442- Deg,    Deguelin, a novel anti-tumorigenic agent targeting apoptosis, cell cycle arrest and anti-angiogenesis for cancer chemoprevention
- Review, Var, NA
PI3K/Akt↓, IKKα↓, AMP↓, mTOR↓, survivin↓, NF-kB↓, Apoptosis↑, TumCCA↑, toxicity↓, HSP90↓, Casp↑, TumCG↓, p27↑, cycE/CCNE↓, angioG↓, Hif1a↓, VEGF↓, *toxicity↑,
1605- EA,    Ellagic Acid and Cancer Hallmarks: Insights from Experimental Evidence
- Review, Var, NA
*BioAv↓, antiOx↓, Inflam↓, TumCP↓, TumCCA↑, cycD1/CCND1↓, cycE/CCNE↓, P53↑, P21↑, COX2↓, NF-kB↓, Akt↑, NOTCH↓, CDK2↓, CDK6↓, JAK↓, STAT3↓, EGFR↓, p‑ERK↓, p‑Akt↓, p‑STAT3↓, TGF-β↓, SMAD3↓, CDK6↓, Wnt/(β-catenin)↓, Myc↓, survivin↓, CDK8↓, PKCδ↓, tumCV↓, RadioS↑, eff↑, MDM2↓, XIAP↓, p‑RB1↓, PTEN↑, p‑FAK↓, Bax:Bcl2↑, Bcl-xL↓, Mcl-1↓, PUMA↑, NOXA↑, MMP↓, Cyt‑c↑, ROS↑, Ca+2↝, Endoglin↑, Diablo↑, AIF↑, iNOS↓, Casp9↑, Casp3↑, cl‑PARP↑, RadioS↑, Hif1a↓, HO-1↓, HO-2↓, SIRT1↓, selectivity↑, Dose∅, NHE1↓, Glycolysis↓, GlucoseCon↓, lactateProd↓, PDK1?, PDK1?, ECAR↝, COX1↓, Snail↓, Twist↓, cMyc↓, Telomerase↓, angioG↓, MMP2↓, MMP9↓, VEGF↓, Dose↝, PD-L1↓, eff↑, SIRT6↑, DNAdam↓,
3238- EGCG,    Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications
- Review, Var, NA
Telomerase↓, DNMTs↓, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, CDK6↓, HATs↓, HDAC↓, selectivity↑, uPA↓, NF-kB↓, TNF-α↓, *ROS↓, *antiOx↑, Hif1a↓, VEGF↓, MMP2↓, MMP9↓, FAK↓, TIMP2↑, Mcl-1↓, survivin↓, XIAP↓, PCNA↓, p16↑, P21↑, p27↑, pRB↑, P53↑, MDM2↑, ROS↑, Casp3↑, Casp8↑, Casp9↑, Cyt‑c↑, Diablo↑, BAX⇅, cl‑PPARα↓, PDGF↓, EGFR↓, FOXO↑, AP-1↓, JNK↓, COX2↓, angioG↓,
2825- FIS,    Exploring the molecular targets of dietary flavonoid fisetin in cancer
- Review, Var, NA
*Inflam↓, *antiOx↓, *ERK↑, *p‑cMyc↑, *NRF2↑, *GSH↑, *HO-1↑, mTOR↓, PI3K↓, Akt↓, TumCCA↑, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, CDK6↓, P21↑, p27↑, JNK↑, MMP2↓, MMP9↓, uPA↓, NF-kB↓, cFos↓, cJun↓, E-cadherin↑, Vim↓, N-cadherin↓, EMT↓, MMP↓, Cyt‑c↑, Diablo↑, Casp↑, cl‑PARP↑, P53↑, COX2↓, PGE2↓, HSP70/HSPA5↓, HSP27↓, DNAdam↑, Casp3↑, Casp9↑, ROS↑, AMPK↑, NO↑, Ca+2↑, mTORC1↓, p70S6↓, ROS↓, ER Stress↑, IRE1↑, ATF4↑, GRP78/BiP↑, eff↑, eff↑, eff↑, RadioS↑, ChemoSen↑, Half-Life↝,
2839- FIS,    Dietary flavonoid fisetin for cancer prevention and treatment
- Review, Var, NA
DNAdam↑, ROS↑, Apoptosis↑, Bcl-2↓, BAX↑, cl‑Casp9↑, cl‑Casp3↑, Cyt‑c↑, lipid-P↓, TumCG↓, TumCA↓, TumCMig↓, TumCI↓, uPA↓, ERK↓, MMP9↓, NF-kB↓, cFos↓, cJun↓, AP-1↓, TumCCA↑, AR↓, mTORC1↓, mTORC2↓, TSC2↑, EGF↓, TGF-β↓, EMT↓, P-gp↓, PI3K↓, Akt↓, mTOR↓, eff↑, ROS↓, ER Stress↑, IRE1↑, ATF4↑, GRP78/BiP↑, ChemoSen↑, CDK2↓, CDK4↓, cycE/CCNE↓, cycD1/CCND1↓, P21↑, COX2↓, Wnt↓, EGFR↓, β-catenin/ZEB1↓, TCF-4↓, MMP7↓, RadioS↑, eff↑,
2843- FIS,    Fisetin and Quercetin: Promising Flavonoids with Chemopreventive Potential
- Review, Var, NA
NRF2↑, Keap1↓, ChemoSen↑, BioAv↓, Cyt‑c↑, Casp3↑, Casp9↑, BAX↑, tumCV↓, Mcl-1↓, cl‑PARP↑, IGF-1↓, Akt↓, CDK6↓, TumCCA↑, P53?, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, CDK6↓, MMP2↓, MMP9↓, MMP1↓, MMP7↓, MMP3↓, VEGF↓, PI3K↓, mTOR↓, COX2↓, Wnt↓, EGFR↓, NF-kB↓, ERK↓, ROS↑, angioG↓, TNF-α↓, PGE2↓, iNOS↓, NO↓, IL6↓, HSP70/HSPA5↝, HSP27↝,
2832- FIS,    Fisetin's Promising Antitumor Effects: Uncovering Mechanisms and Targeting for Future Therapies
- Review, Var, NA
MMP↓, mtDam↑, Cyt‑c↑, Diablo↑, Casp↑, cl‑PARP↑, Bak↑, BIM↑, Bcl-xL↓, Bcl-2↓, P53↑, ROS↑, AMPK↑, Casp9↑, Casp3↑, BID↑, AIF↑, Akt↓, mTOR↓, MAPK↓, Wnt↓, β-catenin/ZEB1↓, TumCCA↑, P21↑, p27↑, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, CDK6↓, TumMeta↓, uPA↓, E-cadherin↑, Vim↓, EMT↓, Twist↓, DNAdam↑, ROS↓, COX2↓, PGE2↓, HSF1↓, cFos↓, cJun↓, AP-1↓, Mcl-1↓, NF-kB↓, IRE1↑, ER Stress↑, ATF4↑, GRP78/BiP↑, MMP2↓, MMP9↓, TCF-4↓, MMP7↓, RadioS↑, TOP1↓, TOP2↓,
2891- HNK,    Honokiol, an Active Compound of Magnolia Plant, Inhibits Growth, and Progression of Cancers of Different Organs
- Review, Var, NA
AntiCan↑, Inflam↓, antiOx↑, selectivity↑, *toxicity↓, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, TumMeta↓, NADPH↓, MMP2↓, MMP9↓, p‑mTOR↓, EGFR↓, EMT↓, SIRT1↑, SIRT3↑, EZH2↓, Snail↓, Vim↓, N-cadherin↓, E-cadherin↑, COX2↓, NF-kB↓, *ROS↓, Ca+2↑, ROS↑,
3275- Lyco,    Multifaceted Effects of Lycopene: A Boulevard to the Multitarget-Based Treatment for Cancer
- Review, Var, NA
TumCCA↑, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, P21↑, P53↑, GSK‐3β↓, p27↓, Akt↓, mTOR↓, ROS↓, MMPs↓, TumCI↓, TumCMig↓, NF-kB↓, *iNOS↓, *COX2↓, lipid-P↓, GSH↑, NRF2↑,
3277- Lyco,    Recent trends and advances in the epidemiology, synergism, and delivery system of lycopene as an anti-cancer agent
- Review, Var, NA
antiOx↑, TumCP↓, Apoptosis↑, TumMeta↑, ChemoSen↑, BioAv↓, Dose↝, BioAv↓, BioAv↑, SOD↑, Catalase↑, GPx↑, IL2↑, IL4↑, IL1↑, TNF-α↑, GSH↑, GPx↑, GSTA1↑, GSR↑, PPARγ↑, Casp3↑, NF-kB↓, COX2↓, Bcl-2↑, BAX↓, P53↓, CHK1↓, Chk2↓, γH2AX↓, DNAdam↓, ROS↓, P21↑, PCNA↓, β-catenin/ZEB1↓, PGE2↓, ERK↓, cMyc↓, cycE/CCNE↓, JAK1↓, STAT3↓, SIRT1↑, cl‑PARP↑, cycD1/CCND1↓, TNF-α↓, IL6↓, p65↓, MMP2↓, MMP9↓, Wnt↓,
4791- Lyco,    Investigating into anti-cancer potential of lycopene: Molecular targets
- Review, Var, NA
*antiOx↑, TumCP↓, TumCCA↓, Apoptosis↑, TumCI↓, angioG↓, TumMeta↓, *Risk↓, cycD1/CCND1↓, CycD3↓, cycE/CCNE↓, CDK2↓, CDK4↓, Bcl-2↓, P21↑, p27↑, P53↑, BAX↑, selectivity↑, MMP↓, Cyt‑c↑, Wnt↓, eff↑, PPARγ↑, LDL↓, Akt↓, PI3K↓, mTOR↓, PDGF↓, NF-kB↓, eff↑,
4514- MAG,    Magnolol and its semi-synthetic derivatives: a comprehensive review of anti-cancer mechanisms, pharmacokinetics, and future therapeutic potential
- Review, Var, NA
AntiCan↑, TumCP↓, TumCCA↑, TumMeta↓, angioG↓, NF-kB↓, MAPK↓, PI3K↓, Akt↓, mTOR↓, BioAv↓, *antiOx↑, *Inflam↓, *AntiAg↑, ChemoSen↑, cycD1/CCND1↓, CycB/CCNB1↓, cycE/CCNE↓, CDK2↓, CDK4↓, p27↑, P21↑, P53↑, PTEN↓, XIAP↓, Mcl-1↓, Casp3↑, Casp9↑, MMP9↑,
5800- MET,    Metformin as anticancer agent and adjuvant in cancer combination therapy: Current progress and future prospect
- Review, Var, NA
ChemoSen↑, RadioS↑, Imm↑, *AntiDiabetic↑, *AMPK↑, TumCP↓, hepatoP↑, ATP↓, AMP↑, glucoNG↓, ROS↑, compI↓, DNAdam↑, CSCs↓, NP/CIPN↓, chemoP↑, toxicity↓, Trx↓, eff↑, cycD1/CCND1↓, CDK4↓, CDK6↓, cycE/CCNE↓, CDK2↓,
1676- PBG,    Use of Stingless Bee Propolis and Geopropolis against Cancer—A Literature Review of Preclinical Studies
- Review, Var, NA
ROS↑, MMP↓, Bcl-2↓, eff↑, tumCV↓, TumCCA↑, angioG↓, PAK1↓, HDAC1↓, HDAC2↓, P53↑, PCNA↓, cycD1/CCND1↓, cycE/CCNE↓, P21?, BAX↑, cl‑Casp3↑, cl‑PARP↑, ChemoSen↑,
3930- PTS,    A Review of Pterostilbene Antioxidant Activity and Disease Modification
- Review, Var, NA - Review, adrenal, NA - Review, Stroke, NA
*BioAv↑, *antiOx↑, *neuroP↑, *Inflam↓, *ROS↓, *H2O2↓, *GSH↑, *GPx↑, *GSR↑, *SOD↑, TumCG↓, PTEN↑, HGF/c-Met↓, PI3K↓, Akt↓, NF-kB↓, TumMeta↓, MMP2↓, MMP9↓, Ki-67↓, Casp3↑, MMP↓, H2O2↑, ROS↑, ChemoSen↑, *cardioP↑, *CDK2↓, *CDK4↓, *cycE/CCNE↓, *cycD1/CCND1↓, *RB1↓, *PCNA↓, *CREB↑, *GABA↑, *memory↑, *IGF-1↑, *ERK↑, TIMP1↑, BAX↑, Cyt‑c↑, Diablo↑, SOD2↑,
3354- QC,    Quercetin: Its Main Pharmacological Activity and Potential Application in Clinical Medicine
- Review, Var, NA
*ROS↓, *IronCh↓, *lipid-P↓, *GSH↑, *NRF2↑, TumCCA↑, ER Stress↑, P53↑, CDK2↓, cycA1/CCNA1↓, CycB/CCNB1↓, cycE/CCNE↓, cycD1/CCND1↓, PCNA↓, P21↑, p27↑, PI3K↓, Akt↓, mTOR↓, STAT3↓, cFLIP↓, cMyc↓, survivin↓, DR5↓, *Inflam↓, *IL6↓, *IL8↓, COX2↓, 5LO↓, *cardioP↑, *FASN↓, *AntiAg↑, *MDA↓,
1726- SFN,    Sulforaphane: A Broccoli Bioactive Phytocompound with Cancer Preventive Potential
- Review, Var, NA
Dose↝, eff↝, IL1β↓, IL6↓, IL12↓, TNF-α↓, COX2↓, CXCR4↓, MPO↓, HSP70/HSPA5↓, HSP90↓, VCAM-1↓, IKKα↓, NF-kB↓, HO-1↑, Casp3↑, Casp7↑, Casp8↑, Casp9↑, cl‑PARP↑, Cyt‑c↑, Diablo↑, CHOP↑, survivin↓, XIAP↓, p38↑, Fas↑, PUMA↑, VEGF↓, Hif1a↓, Twist↓, Zeb1↓, Vim↓, MMP2↓, MMP9↓, E-cadherin↑, N-cadherin↓, Snail↓, CD44↓, cycD1/CCND1↓, cycA1/CCNA1↓, CycB/CCNB1↓, cycE/CCNE↓, CDK4↓, CDK6↓, p50↓, P53↑, P21↑, GSH↑, SOD↑, GSTs↑, mTOR↓, Akt↓, PI3K↓, β-catenin/ZEB1↓, IGF-1↓, cMyc↓, CSCs↓,
3290- SIL,    A review of therapeutic potentials of milk thistle (Silybum marianum L.) and its main constituent, silymarin, on cancer, and their related patents
- Analysis, Var, NA
hepatoP↑, chemoP↑, *lipid-P↓, *antiOx↑, tumCV↓, TumCMig↓, Apoptosis↑, ROS↑, GSH↓, Bcl-2↓, survivin↓, cycD1/CCND1↓, NOTCH1↓, BAX↑, NF-kB↓, COX2↓, LOX1↓, iNOS↓, TNF-α↓, IL1↓, Inflam↓, *toxicity↓, CXCR4↓, EGFR↓, ERK↓, MMP↓, Cyt‑c↑, TumCCA↑, RB1↑, P53↑, P21↑, p27↑, cycE/CCNE↓, CDK4↓, p‑pRB↓, Hif1a↓, cMyc↓, IL1β↓, IFN-γ↓, PCNA↓, PSA↓, CYP1A1↓,

Showing Research Papers: 1 to 23 of 23

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 23

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

antiOx↓, 1,   antiOx↑, 2,   ATF3↑, 1,   Catalase↑, 1,   compI↓, 1,   CYP1A1↓, 1,   GPx↑, 2,   GSH↓, 1,   GSH↑, 3,   GSR↑, 2,   GSTA1↑, 1,   GSTs↑, 1,   H2O2↑, 1,   HO-1↓, 1,   HO-1↑, 2,   HO-2↓, 1,   Keap1↓, 1,   lipid-P?, 1,   lipid-P↓, 2,   lipid-P↑, 1,   MPO↓, 1,   NQO1↑, 1,   NRF2↑, 3,   ROS↓, 5,   ROS↑, 14,   SIRT3↑, 2,   SOD↑, 2,   SOD2↑, 1,   Trx↓, 1,  

Metal & Cofactor Biology ⓘ

Tf↓, 1,  

Mitochondria & Bioenergetics ⓘ

ADP:ATP↑, 1,   AIF↑, 2,   ATP↓, 1,   CDC2↓, 1,   CDC25↓, 1,   EGF↓, 1,   mitResp↓, 1,   MMP↓, 8,   mtDam↑, 2,   Raf↓, 1,   XIAP↓, 4,  

Core Metabolism/Glycolysis ⓘ

AMP↓, 1,   AMP↑, 1,   AMPK↑, 2,   cMyc↓, 6,   ECAR↝, 1,   glucoNG↓, 1,   GlucoseCon↓, 2,   Glycolysis↓, 2,   lactateProd↓, 2,   LDHA↓, 1,   LDL↓, 1,   NADPH↓, 1,   NADPH↑, 1,   PDK1?, 2,   PI3K/Akt↓, 1,   PKM2↓, 1,   PPARα↓, 1,   cl‑PPARα↓, 1,   PPARγ↑, 3,   SIRT1↓, 2,   SIRT1↑, 2,  

Cell Death ⓘ

Akt↓, 12,   Akt↑, 1,   p‑Akt↓, 1,   Apoptosis↑, 7,   Bak↑, 1,   BAX↓, 1,   BAX↑, 7,   BAX⇅, 1,   Bax:Bcl2↑, 1,   Bcl-2↓, 7,   Bcl-2↑, 1,   Bcl-xL↓, 2,   BID↑, 1,   BIM↑, 1,   Casp↑, 3,   Casp3↓, 1,   Casp3↑, 10,   cl‑Casp3↑, 3,   Casp7↑, 1,   Casp8↑, 4,   Casp9↑, 8,   cl‑Casp9↑, 2,   cFLIP↓, 1,   Chk2↓, 2,   Cyt‑c↑, 13,   Diablo↑, 6,   DR4↑, 1,   DR5↓, 1,   DR5↑, 2,   FADD↑, 1,   Fas↑, 2,   HEY1↓, 1,   HGF/c-Met↓, 1,   iNOS↓, 3,   JNK↓, 2,   JNK↑, 2,   MAPK↓, 2,   MAPK↑, 1,   Mcl-1↓, 7,   MDM2↓, 2,   MDM2↑, 1,   Myc↓, 1,   NOXA↑, 1,   p27↓, 1,   p27↑, 9,   p38↑, 3,   PUMA↑, 2,   survivin↓, 7,   Telomerase↓, 2,   TRPV1↑, 1,   TumCD↑, 1,  

Kinase & Signal Transduction ⓘ

p70S6↓, 1,   TSC2↑, 1,  

Transcription & Epigenetics ⓘ

cJun↓, 3,   EZH2↓, 1,   H3↑, 1,   HATs↓, 1,   pRB↑, 1,   p‑pRB↓, 1,   tumCV↓, 4,  

Protein Folding & ER Stress ⓘ

CHOP↑, 2,   ER Stress↓, 1,   ER Stress↑, 6,   GRP78/BiP↑, 5,   HSF1↓, 1,   HSP27↓, 1,   HSP27↝, 1,   HSP70/HSPA5↓, 3,   HSP70/HSPA5↝, 1,   HSP90↓, 3,   IRE1↑, 3,  

Autophagy & Lysosomes ⓘ

Beclin-1↑, 1,   TumAuto↑, 1,  

DNA Damage & Repair ⓘ

CHK1↓, 2,   DNAdam↓, 2,   DNAdam↑, 5,   DNMTs↓, 1,   p16↑, 1,   P53?, 1,   P53↓, 1,   P53↑, 13,   PARP↑, 1,   cl‑PARP↑, 9,   PCNA↓, 6,   SIRT6↑, 1,   γH2AX↓, 1,   γH2AX↑, 1,  

Cell Cycle & Senescence ⓘ

CDK1↓, 1,   CDK2↓, 16,   CDK4↓, 18,   cycA1/CCNA1↓, 3,   CycB/CCNB1↓, 5,   cycD1/CCND1↓, 18,   CycD3↓, 1,   cycE/CCNE↓, 22,   E2Fs↓, 1,   P21?, 1,   P21↑, 15,   RB1↑, 1,   p‑RB1↓, 3,   TumCCA↓, 1,   TumCCA↑, 14,  

Proliferation, Differentiation & Cell State ⓘ

CD44↓, 1,   CDK8↓, 1,   cFos↓, 3,   CSCs↓, 3,   EMT↓, 6,   ERK↓, 5,   p‑ERK↓, 2,   FOXO↑, 1,   FOXO3↑, 1,   GSK‐3β↓, 1,   HDAC↓, 1,   HDAC1↓, 1,   HDAC2↓, 1,   HH↓, 1,   IGF-1↓, 2,   Let-7↑, 1,   mTOR↓, 10,   p‑mTOR↓, 1,   mTORC1↓, 2,   mTORC2↓, 1,   NOTCH↓, 2,   NOTCH1↓, 1,   PI3K↓, 9,   PTEN↓, 1,   PTEN↑, 2,   STAT3↓, 5,   p‑STAT3↓, 2,   TCF-4↓, 2,   TOP1↓, 2,   TOP2↓, 2,   TOP2↑, 1,   TumCG↓, 3,   Wnt↓, 6,   Wnt/(β-catenin)↓, 1,  

Migration ⓘ

5LO↓, 1,   AP-1↓, 5,   AXL↓, 1,   Ca+2↑, 4,   Ca+2↝, 1,   CAFs/TAFs↓, 1,   Cdc42↑, 1,   E-cadherin↑, 5,   ER-α36↓, 1,   FAK↓, 1,   p‑FAK↓, 1,   Ki-67↓, 2,   miR-200b↑, 1,   MMP1↓, 2,   MMP2↓, 12,   MMP3↓, 1,   MMP7↓, 4,   MMP9↓, 14,   MMP9↑, 1,   MMPs↓, 2,   N-cadherin↓, 4,   PAK1↓, 1,   PDGF↓, 3,   PKCδ↓, 2,   Slug↓, 2,   SMAD3↓, 1,   Snail?, 1,   Snail↓, 4,   TGF-β↓, 3,   TIMP1↑, 1,   TIMP2↑, 2,   TumCA↓, 1,   TumCI↓, 4,   TumCMig↓, 3,   TumCP↓, 7,   TumMeta↓, 8,   TumMeta↑, 1,   Twist↓, 4,   uPA↓, 7,   VCAM-1↓, 1,   Vim↓, 5,   Zeb1↓, 2,   ZEB2↓, 1,   β-catenin/ZEB1↓, 6,  

Angiogenesis & Vasculature ⓘ

angioG↓, 11,   ATF4↑, 4,   EGFR↓, 6,   Endoglin↑, 1,   Hif1a↓, 6,   LOX1↓, 1,   NO↓, 1,   NO↑, 1,   PDGFR-BB↓, 1,   p‑PDGFR-BB↓, 1,   VEGF↓, 10,   VEGFR2↓, 1,  

Barriers & Transport ⓘ

GLUT1↓, 1,   NHE1↓, 1,   P-gp↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX1↓, 1,   COX2↓, 15,   CXCR4↓, 3,   IFN-γ↓, 1,   IKKα↓, 3,   IL1↓, 1,   IL1↑, 1,   IL12↓, 1,   IL1α↓, 1,   IL1β↓, 2,   IL2↑, 1,   IL4↓, 1,   IL4↑, 1,   IL6↓, 3,   IL8↓, 1,   Imm↑, 1,   Inflam↓, 3,   JAK↓, 1,   JAK1↓, 1,   M2 MC↓, 1,   MCP1↓, 1,   MIP2↓, 1,   NF-kB↓, 18,   p50↓, 1,   p65↓, 1,   PD-L1↓, 1,   PGE2↓, 4,   PSA↓, 1,   TNF-α↓, 5,   TNF-α↑, 1,  

Synaptic & Neurotransmission ⓘ

5HT↓, 1,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 2,   CDK6↓, 11,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 6,   BioAv↑, 4,   ChemoSen↑, 9,   Dose↑, 1,   Dose↝, 3,   Dose∅, 1,   eff↓, 1,   eff↑, 25,   eff↝, 1,   Half-Life↓, 2,   Half-Life↝, 1,   RadioS↑, 6,   selectivity↑, 6,  

Clinical Biomarkers ⓘ

AR↓, 2,   ascitic↓, 1,   E6↓, 1,   E7↓, 1,   EGFR↓, 6,   EZH2↓, 1,   IL6↓, 3,   Ki-67↓, 2,   Myc↓, 1,   PD-L1↓, 1,   PSA↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 3,   chemoP↑, 2,   chemoPv↑, 2,   hepatoP↑, 2,   NP/CIPN↓, 1,   RenoP↑, 1,   toxicity↓, 3,   TumVol↓, 1,  
Total Targets: 322

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↓, 1,   antiOx↑, 6,   GPx↑, 1,   GSH↑, 3,   GSR↑, 1,   H2O2↓, 1,   HO-1↑, 1,   lipid-P↓, 2,   MDA↓, 1,   NRF2↑, 2,   Prx↑, 1,   ROS↓, 4,   SOD↑, 1,   SOD2↑, 1,  

Metal & Cofactor Biology ⓘ

IronCh↓, 1,  

Core Metabolism/Glycolysis ⓘ

AMPK↑, 1,   p‑cMyc↑, 1,   CREB↑, 1,   FASN↓, 1,  

Cell Death ⓘ

Casp3?, 1,   iNOS↓, 1,   MAPK↑, 1,  

DNA Damage & Repair ⓘ

PCNA↓, 1,  

Cell Cycle & Senescence ⓘ

CDK2↓, 1,   CDK4↓, 1,   cycD1/CCND1↓, 1,   cycE/CCNE↓, 1,   RB1↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

ERK↑, 2,   IGF-1↑, 1,  

Migration ⓘ

AntiAg↑, 2,   Ca+2↝, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   IL6↓, 1,   IL8↓, 1,   Inflam↓, 6,   NF-kB↓, 1,   TNF-α↓, 1,  

Synaptic & Neurotransmission ⓘ

GABA↑, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 1,   BioAv↑, 1,  

Clinical Biomarkers ⓘ

IL6↓, 1,  

Functional Outcomes ⓘ

AntiDiabetic↑, 1,   cardioP↑, 2,   memory↑, 1,   neuroP↑, 1,   Obesity↓, 1,   Risk↓, 1,   toxicity↓, 3,   toxicity↑, 1,  
Total Targets: 50

Scientific Paper Hit Count for: cycE/CCNE, Cyclin E
4 Fisetin
3 Lycopene
2 Artemisinin
1 Ashwagandha(Withaferin A)
1 Boswellia (frankincense)
1 Capsaicin
1 Deguelin
1 Ellagic acid
1 EGCG (Epigallocatechin Gallate)
1 Honokiol
1 Magnolol
1 Metformin
1 Propolis -bee glue
1 Pterostilbene
1 Quercetin
1 Sulforaphane (mainly Broccoli)
1 Silymarin (Milk Thistle) silibinin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:26  Cells:%  prod#:%  Target#:378  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page